Aleafia Health - CEO, Geoffrey Benic
CEO, Geoffrey Benic
Source: Aleafia Health
  • Aleafia Health (AH) has begun to export dried flower into Germany, gaining access to Europe’s most mature legal cannabis market
  • The first shipment, from Aleafia’s Niagara greenhouse facility, features the company’s signature THC cultivar Sour Kush
  • The European cannabis market is expected to be worth US$4.7 billion by 2025, with Germany representing nearly half the total market size
  • The company informs that it is currently fulfilling successive purchase orders to Germany
  • Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company
  • Aleafia Health (AH) is trading flat at $0.44 per share

Aleafia Health (AH) has begun to export dried flower into Germany, gaining access to Europe’s most mature legal cannabis market.

The first shipment, from Aleafia’s Niagara greenhouse facility, features the company’s signature THC cultivar Sour Kush. While dried flower available in Germany is largely irradiated, the product shipped exceeded quality standards and did not require irradiation, offering a significant competitive advantage in product quality.

The company completed the export through a strategic partner’s EU-GMP-certified facility.

Germany is the second major medical cannabis market the company has exported to.

The European cannabis market is expected to be worth US$4.7 billion by 2025, with Germany alone representing nearly half the total market size, according to research from Prohibition Partners.

The company informs that it is currently fulfilling successive purchase orders to Germany.

In addition, Aleafia has secured import and export permits for two additional orders to Australia with shipments expected to occur in June.

 Geoffrey Benic, Aleafia Health’s CEO, commented,

“The investments we’ve made in the highest levels of global regulatory compliance are just now beginning to pay dividends as we gain access to the largest medical cannabis market in the world. The shipment itself is an incredibly important breakthrough. More importantly, it represents an entirely new sales channel that will deliver consistent, repeatable revenue.

With such high barriers to entry, the German cannabis market opportunity perfectly complements this quarter’s continued growth in our domestic medical and adult-use channels.”

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company.

Aleafia Health (AH) is trading flat at $0.44 per share as of 11:36 am ET.

More From The Market Online

Buzz on the Bullboards: Challenges amid inflation and geopolitical tensions

Canadian and U.S. stock markets grapple with a host of challenges, from surging inflation data to escalating tensions in the Middle East.

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.

The Market Online’s Weekly Cannabis Report – April 12, 2024

Canada’s cannabis stock market fluctuated this week thanks to a combination of industry-specific developments and broader market trends